Publication:
Severe hepatotoxicity secondary to nintedanib.

Simple item page
dc.contributor.authorLibrero Jiménez, Marta
dc.contributor.authorHeredia Carrasco, Clara
dc.contributor.authorFernández Cano, María Del Carmen
dc.date.accessioned2023-05-03T14:29:18Z
dc.date.available2023-05-03T14:29:18Z
dc.date.issued2022
dc.description.abstractNintedanib is a multikinase inhibitor used for the treatment of pulmonary idiopathic fibrosis. We present the first report published to date of severe hepatotoxicity and jaundice secondary to nintedanib.
dc.identifier.doi10.17235/reed.2020.7585/2020
dc.identifier.issn1130-0108
dc.identifier.pmid33371696
dc.identifier.unpaywallURLhttps://doi.org/10.17235/reed.2020.7585/2020
dc.identifier.urihttp://hdl.handle.net/10668/21700
dc.issue.number4
dc.journal.titleRevista espanola de enfermedades digestivas
dc.journal.titleabbreviationRev Esp Enferm Dig
dc.language.isoen
dc.organizationHospital Universitario Virgen de las Nieves
dc.page.number244-245
dc.pubmedtypeLetter
dc.rights.accessRightsopen access
dc.subject.meshChemical and Drug Induced Liver Injury
dc.subject.meshHumans
dc.subject.meshIdiopathic Pulmonary Fibrosis
dc.subject.meshIndoles
dc.titleSevere hepatotoxicity secondary to nintedanib.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number114
dspace.entity.typePublication

Files

Collections

SAS - Hospital Universitario Virgen de las Nieves

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía